A three-way crossover clinical pharmacological study to evaluate a drug interaction on P-gp at Blood Brain Barrier between histamine H1 receptor antagonist Ebastine and P-gp inhibitor Verapamil by using saccadic eye movement analyzing system and visual analogue scale (VAS) in healthy Japanese male volunteers

A three-way crossover clinical pharmacological study to evaluate a drug interaction on P-gp at Blood Brain Barrier between histamine H1 receptor antagonist Ebastine and P-gp inhibitor Verapamil by using saccadic eye movement analyzing system and visual analogue scale (VAS) in healthy Japanese male volunteers - Clinical pharmacological study to evaluate a drug interaction on P-gp at Blood Brain Barrier between histamine H1 receptor antagonist Ebastine and P-gp inhibitor Verapamil

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000000577

Enrollment

Registered

2007-02-01

Start date

2007-01-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

healthy Japanese male volunteers

Interventions

Ebastin 10 mg single oral dose Ebastin 20 mg single oral dose Ebastin 10 mg single oral dose +Verapamil 80 mg single oral dose

Eligibility

Sex/Gender

Male

Inclusion criteria

Inclusion criteria: 1.Healthy Japanese male volunteer 2.Age from 20<= <40 3.Subjects who can report self condition 4.Without clinically significant abnormalities in a series of screening examination 5.Written informed consent

Exclusion criteria

Exclusion criteria: 1.Any clinically significant history of drug abuse, alcoholic abuse, heart, liver, kidney, lung, and blood disease etc. thought to be not eligible to participate in the study 2.Subjects known to treated with medicine which has a sedative effect or an antihistaminic agents 3.Subjects who can not abstaine from smoking during study period 4. Subjects who have the 1st deg. AV block on their ECG examination at screening visit. 5. Subjects who have any clinically significant abnormalities on their ECG examination at screening visit. 6.Any drug allergy history 7.Subjects who is using excessive alcohol regularly (cannot keep abstinence for study period) 8.Perticipation in any clinical trial within 4 months 9.Donation of more than 200mL blood within 3 months 10.Any use of drugs in the 2 weeks prior to study drug administration 11.Subjects who, in the opinion of the investigator, are not likely to participate in the study for any reason

Design outcomes

Primary

Measure	Time frame
Saccadic eye movement peak velocity	—

Secondary

Measure	Time frame
Other saccadic eve movement parameters (latency) Visual analogue scale alertness score Plasma concentration of Carabastine	—

Countries

Japan

Contacts

Public ContactNaoki UCHIDA MD.,PhD

Showa University School of Medicine Second department of Pharmacology

nuchida@med.showa-u.ac.jp03-3784-8128

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026